ストックスクリーナーアプリを入手
4.87
2.31%
0.11
アフターアワーズ：
4.87
前日終値:
$4.76
開ける：
$4.82
24時間の取引高:
242.43K
Relative Volume:
0.62
時価総額：
$282.18M
収益：
-
当期純損益:
$-68.46M
株価収益率:
-3.6617
EPS:
-1.33
ネットキャッシュフロー:
$-57.37M
1週間 パフォーマンス:
-0.61%
1か月 パフォーマンス:
+9.68%
6か月 パフォーマンス:
+4.96%
1年 パフォーマンス:
+412.58%
1日の値動き範囲:
$4.71
$4.93
1週間の範囲:
$4.47
$4.98
52週間の値動き範囲:
$0.9199
$6.1856
Rezolute Inc Stock (RZLT) Company Profile
名前
Rezolute Inc
セクター
電話
650-206-4507
住所
275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY
RZLT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RZLT
Rezolute Inc
|
4.87 | 282.18M | 0 | -68.46M | -57.37M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Rezolute Inc Stock (RZLT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-05 | 開始されました | Wedbush | Outperform |
| 2024-08-27 | 開始されました | Guggenheim | Buy |
| 2024-07-17 | 開始されました | BTIG Research | Buy |
| 2024-06-04 | 開始されました | Craig Hallum | Buy |
| 2024-04-09 | 開始されました | Maxim Group | Buy |
| 2022-08-02 | 再開されました | Canaccord Genuity | Buy |
| 2022-06-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-09-08 | 開始されました | ROTH Capital | Buy |
| 2021-05-27 | 開始されました | Oppenheimer | Outperform |
| 2021-05-25 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Rezolute Inc (RZLT) 最新ニュース
Rezolute, Inc. (NASDAQ:RZLT) Receives $24.13 Average Target Price from Analysts - Defense World
Brokerages Set Rezolute, Inc. (NASDAQ:RZLT) Price Target at $24.13 - MarketBeat
Rezolute shares Phase 2 clinical study update By Investing.com - Investing.com South Africa
Rezolute shares Phase 2 clinical study update - Investing.com
Rezolute Highlights Promising Phase 2 Ersodetug Results - TipRanks
(RZLT) On The My Stocks Page - Stock Traders Daily
Top 5 Small-cap Biotech Stocks (Updated January 2025) - Investing News Network
Rezolute, Inc. (NASDAQ:RZLT) Shares Acquired by Geode Capital Management LLC - MarketBeat
Rezolute Gains FDA Breakthrough Designation for Ersodetug - TipRanks
Here's Why 'Trend' Investors Would Love Betting on Rezolute (RZLT) - Yahoo Finance
FDA Grants Breakthrough Therapy Status to Rezolute's Ersodetug for Congenital Hyperinsulinism - StockTitan
State Street Corp Acquires 13,000 Shares of Rezolute, Inc. (NASDAQ:RZLT) - Defense World
MML Investors Services LLC Makes New $57,000 Investment in Rezolute, Inc. (NASDAQ:RZLT) - Defense World
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying - Yahoo Finance
Brokerages Set Rezolute, Inc. (NASDAQ:RZLT) Target Price at $24.13 - Defense World
Rezolute, Inc. (NASDAQ:RZLT) Given Average Rating of "Buy" by Analysts - MarketBeat
Rezolute CFO Daron Evans buys $42,900 in company stock By Investing.com - Investing.com Australia
Rezolute CFO Daron Evans buys $42,900 in company stock - Investing.com India
Insider Buying: Rezolute, Inc. (NASDAQ:RZLT) CFO Buys 10,000 Shares of Stock - MarketBeat
Rezolute's SWOT analysis: biotech stock's pipeline progress and market potential - Investing.com Nigeria
Rezolute's SWOT analysis: biotech stock's pipeline progress and market potential By Investing.com - Investing.com South Africa
Chief Financial Officer of Rezolute Daron Evans Buys 6.5% More Shares - Simply Wall St
Rezolute (NASDAQ:RZLT) and BetterLife Pharma (OTCMKTS:PVOTF) Head to Head Comparison - Defense World
When the Price of (RZLT) Talks, People Listen - Stock Traders Daily
Rezolute expands authorized shares following shareholder approval - Investing.com
Daron Evans, CFO of Rezolute, buys $53,166 in common shares By Investing.com - Investing.com Nigeria
Daron Evans, CFO of Rezolute, buys $53,166 in common shares - Investing.com
RZLT Stock Rises on FDA's Orphan Designation for Rare Disease Drug - MSN
Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Rezolute Grants 150,000-Share Inducement Award to New Supply Chain Executive - StockTitan
Rezolute retains steady stock target on Orphan Drug nod By Investing.com - Investing.com Canada
RZLT Stock Rises On FDA's Orphan Designation For Rare Disease Drug - Barchart
FDA Grants Orphan Drug Designation to Rezolute's Ersodetug for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism - Marketscreener.com
Rezolute: Ersodetug Downstream Tech Could Ignite The Hyperinsulinism Market (NASDAQ:RZLT) - Seeking Alpha
Rezolute Receives Orphan-Drug Designation from FDA for Low Blood Sugar Treatment - MarketWatch
FDA Grants Orphan Drug Designation to Rezolute's Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism - The Manila Times
Rezolute's Hypoglycemia Drug Wins FDA Orphan Drug Status; Phase 3 Trial Set for 2025 - StockTitan
Rezolute, Inc. (NASDAQ:RZLT) Receives $24.13 Average Price Target from Analysts - MarketBeat
Rezolute, Inc. Advances Late-Stage Trials for Rare Disease Therapies - TipRanks
BTIG Initiates Coverage of Rezolute (RZLT) with Buy Recommendation - MSN
Rezolute, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended June 30, 2024 - Marketscreener.com
Wedbush Initiates Coverage of Rezolute (RZLT) with Outperform Recommendation - MSN
Institutional investors in Rezolute, Inc. (NASDAQ:RZLT) lost 11% last week but have reaped the benefits of longer-term growth - Simply Wall St
Is Rezolute, Inc. (RZLT) the Best Multibagger Stock to Buy Heading into 2025? - Insider Monkey
Rezolute Inc (RZLT) 財務データ
収益
当期純利益
現金流量
EPS
Rezolute Inc (RZLT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Evans Daron | CFO |
Dec 12 '24 |
Buy |
4.60 |
9,000 |
41,400 |
140,900 |
| Evans Daron | CFO |
Dec 09 '25 |
Buy |
5.04 |
10,549 |
53,167 |
131,900 |
| Hogenhuis Wladimir | Director |
Sep 24 '24 |
Buy |
4.70 |
4,259 |
20,017 |
41,767 |
| Hogenhuis Wladimir | Director |
Jun 25 '24 |
Buy |
4.15 |
4,815 |
19,982 |
37,508 |
| ROBERTS BRIAN KENNETH | Chief Medical Officer |
Jun 14 '24 |
Buy |
3.91 |
4,300 |
16,828 |
54,352 |
| ROBERTS BRIAN KENNETH | Chief Medical Officer |
Jun 14 '24 |
Buy |
3.91 |
3,300 |
12,916 |
13,000 |
| Evans Daron | CFO |
Jun 14 '24 |
Buy |
4.04 |
40,000 |
161,568 |
40,000 |
| Evans Daron | CFO |
May 29 '24 |
Buy |
3.50 |
451 |
1,578 |
121,351 |
| ROBERTS BRIAN KENNETH | Chief Medical Officer |
May 23 '24 |
Buy |
2.69 |
7,500 |
20,138 |
50,052 |
| Evans Daron | CFO |
May 24 '24 |
Buy |
3.23 |
2,942 |
9,503 |
13,000 |
0.65%
4.62%
大文字化:
|
ボリューム (24 時間):